SCHEMBL24596272

SCHEMBL24596272

COc1ccc(Nc2nc(C(F)(F)F)ccc2Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.45
NTRK2 Q16620 1/20 0.45
SYK P43405 3/20 0.45
AURKA O14965 2/20 0.45
MAPT P10636 4/20 0.44
GAA P10253 3/20 0.44
RAB9A P51151 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
THRB P10828 1/20 0.44
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NR4A1 P22736 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26631662 0.83 ROCK1 (0.42) SYKMAPTNPSR1ALDH1A1HTT
SCHEMBL24596239 0.81 NR1I2 (0.42) MAPTGAARAB9AL3MBTL1KDM4E
SCHEMBL24596349 0.75 CDK19 (0.46) NTRK2AURKAMAPTGAARAB9A
SCHEMBL24596212 0.72 ULK1 (0.44) SYKGAAL3MBTL1MEN1KMT2A
SCHEMBL24596326 0.72 TYK2 (0.46) SYKMAPT
SCHEMBL26756689 0.71 KIF11 (0.48) SYKKDM4EKMT2A
SCHEMBL30649421 0.71 KIF11 (0.48) SYKKDM4EKMT2A
SCHEMBL24596311 0.71 SYK (0.45) SYKMAPTALDH1A1SMN1; SMN2
SCHEMBL24596389 0.70 IGF1R (0.48) SYKMAPTGAAKDM4ENPC1
SCHEMBL22718954 0.70 CHEK1 (0.58) CHEK1NTRK2SYKAURKACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A CHEK1 3787/4885NTRK2 4373/4885SYK 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.